Letters, Testimony & Filings Letter to the FDA Opposing Marketing Authorization of AvertD for Identifying Patients at Increased Genetic Risk of Opioid Use Disorder December 7, 2022
Testimony Before the FDA’s Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee Regarding Pulse Oximeters November 1, 2022
Letters, Testimony & Filings Testimony Before the FDA’s Clinical Chemistry and Clinical Toxicology Devices Panel Opposing Marketing Authorization of the AvertD Genetic Test to Predict the Risk of Opioid Use Disorder October 20, 2022
Outrage of the Month: For Years, FDA Has Allowed the Marketing of Blood Oxygen Monitors that Contributed to Racial Disparities in Health Care August 1, 2022
Outrage of the Month: CPSC Drags Its Feet, Proposes Half Measures as Fatalities Caused by Adult Portable Bed Rails Mount May 1, 2022
Letters, Testimony & Filings Letter to Congress Regarding Legislation to Reauthorize PDUFA and MDUFA April 25, 2022
Comments Submitted to the FDA Regarding Reauthorization of the Medical Device User Fee Amendments for Fiscal Years 2023 Through 2027 (MDUFA V) April 21, 2022
Letters, Testimony & Filings Testimony at the FDA’s Public Meeting Regarding Medical Device User Fee Amendments for Fiscal Years 2023 Through 2027 April 19, 2022